UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009218
Receipt number R000010828
Scientific Title A Phase IV Clinical Trial of EMPYNASE P Tablets 18000 in Patients with ankle swelling after lateral ankle sprain injuries.
Date of disclosure of the study information 2012/10/31
Last modified on 2015/11/04 12:08:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Phase IV Clinical Trial of EMPYNASE P Tablets 18000 in Patients with ankle swelling after lateral ankle sprain injuries.

Acronym

A Phase IV Clinical Trial of EMPYNASE P Tablets 18000 in Patients with ankle swelling after lateral ankle sprain injuries.

Scientific Title

A Phase IV Clinical Trial of EMPYNASE P Tablets 18000 in Patients with ankle swelling after lateral ankle sprain injuries.

Scientific Title:Acronym

A Phase IV Clinical Trial of EMPYNASE P Tablets 18000 in Patients with ankle swelling after lateral ankle sprain injuries.

Region

Japan


Condition

Condition

ankle swelling after lateral ankle sprain injuries.

Classification by specialty

Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy of EMPYNASE P Tablets in combination with the RICE (rest, ice, compression, and elevation) regimen and applying Flurbiprofen cataplasms to ankle sprain injuries as the standard therapy compared to placebo for 1 week in patients with ankle swelling after lateral ankle sprain injuries by double-blind, parallel group comparative study.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase IV


Assessment

Primary outcomes

Change in ankle-foot volume from baseline.

Key secondary outcomes

Change in ankle circumference from baseline.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

EMPYNASE group
EMPYNASE, The RICE (rest, ice, compression, and elevation) regimen &
Flurbiprofen patch application.

Interventions/Control_2

Placebo group
Placebo, The RICE (rest, ice, compression, and elevation) regimen &
Flurbiprofen patch application.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

- Patient with ankle sprain after lateral ankle sprain injuries.
- Patient with ankle swelling after lateral ankle sprain injuries.
- Patient who can be measured the ankle-foot volume 24-60 hours after lateral sprain injuries.

Key exclusion criteria

- Patient with a surgical operation of ankle sprains
- Patient with history of ankle surgeries or with planned ankle surgeries at the sprain side.
- Patient coexisting with arthritis/ Arthritis Charcot-type / diabetic foot/ varicose vein/ etc.
- Patient coexisting with systemic or localised edema.
- Patient with history of drug-indused hypersensitivity.
- Patient coexisting with coagulopathy.
- Patient coexisting with aspirin induced asthma or history of the same.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takeshi Muneta

Organization

Tokyo Medical and Dental University

Division name

Department of Joint Surgery and Sports Medicine

Zip code


Address

1-5-45, Yushima, Bunkyo-ku, Tokyo, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Toshiyuki Yorozuya

Organization

Kaken Pharmaceutical Co., LTD

Division name

Clinical Development Department

Zip code


Address

28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, Japan

TEL

03-5977-5111

Homepage URL


Email



Sponsor or person

Institute

Kaken Pharmaceutical Co., LTD

Institute

Department

Personal name



Funding Source

Organization

Kaken Pharmaceutical Co., LTD

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

JAPAN


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 10 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 10 Month 04 Day

Date of IRB


Anticipated trial start date

2012 Year 11 Month 01 Day

Last follow-up date

2014 Year 10 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 10 Month 30 Day

Last modified on

2015 Year 11 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010828


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name